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Muscarinic acetylcholine receptors have been extensively studied 
with the purpose of finding selective ligands for their modulation. 
In the last years, a new strategy was developed towards this 
aim, i.e. the synthesis of so-called dualsteric ligands that bind 
simultaneously to both the orthosteric and the allosteric site of 
the M2 receptor.Two dualsteric compounds, Iper-6-naph and Isox-
6-naph, and their orthosteric fragments were studied in GTPγS 
assays and [3H]NMS binding studies, performed with membranes 
of CHO cells expressing the human M2 receptor. The experi-
ments were carried out in Tris buffer supplemented with either 2 
mM or 200 mM NaCl, in order to have the receptor in its spon-
taneously active or inactive conformations, respectively. In both 
buffers, Iper-6-naph was a partial agonist and it almost completely 
abolished [3H]NMS binding. In contrast, Isox-6-naph revealed 
a protean nature, behaving either as inverse or partial agonist, 
respectively, in 2 mM and 200 mM NaCl, and it promoted [3H]
NMS binding. Since the two hybrid compounds share the same 
allosteric moiety, these discrepancies have to be attributed to 
pharmacological differences of the orthosteric moieties, whose 
potencies and affinities were indeed reported to be significantly 
divergent. In conclusion, this study suggests that slight structural 
modifications in the orthosteric building block of dualsteric ligands 
may cause a reversal of ligand efficacy and, most importantly, 
it provides a deeper insight into the molecular determinants of 
protean agonism at the M2 receptor.
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